RxDoctor Payments Data

John Taylor, DPM

Podiatrist · El Paso, TXNPI 1093771388

Payments from drug & device makers

$10,869in general payments, 2019–2025

Across 160 payments — averaging $67.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$3K
  • Treace Medical Concepts, Inc.$3K
  • Nvision Biomedical Technologies, Inc.$2K
  • Smith+Nephew$640
  • Kerecis Limited$458
  • Paragon 28, Inc.$391
  • plus $2K from 12 others

What the payments were for

  • Travel & lodging$6,56760%
  • Food & beverage$4,30240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,869 in reported general payments places this provider in the 80th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$98,086
Medicare patients
279
Services billed
1,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol EmollientClobetasol Propionate/Emoll65$35,075
Desonide59$29,723
Diclofenac Sodium35$22,232
SantylCollagenase Clostridium Hist.37$22,200
Clobetasol Propionate75$20,381
Mometasone Furoate54$4,548
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc23$3,713
Ciclopirox84$2,545
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip61$1,287
Gabapentin111$728
Ammonium Lactate25$626
Triamcinolone Acetonide30$564
Cephalexin35$498
Terbinafine Hcl37$396
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim38$279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$640$22,20037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 470 podiatrist providers in Texas.

Other podiatrist in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →